MedPath

Risperidone

Generic Name
Risperidone
Brand Names
Perseris, Risperdal, Rykindo, Uzedy, Okedi
Drug Type
Small Molecule
Chemical Formula
C23H27FN4O2
CAS Number
106266-06-2
Unique Ingredient Identifier
L6UH7ZF8HC
Background

Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).

Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain.

Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets which may responsible for some of its undesirable effects.

Indication

Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.

Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.

Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.

Associated Conditions
Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state

Risperidone for the Treatment of Cocaine Dependence - 7

Phase 2
Completed
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-16
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000342
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Infusion Laboratory: Protocol 3 (Risperidone) - 4

Phase 1
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-11
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Target Recruit Count
13
Registration Number
NCT00000339
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1

Phase 2
Terminated
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2015-07-24
Lead Sponsor
Butler Hospital
Registration Number
NCT00000309
Locations
🇺🇸

Brown University School of Medicine, Providence, Rhode Island, United States

Risperidone for Treatment of Cocaine Dependence in Outpatients - 12

Phase 2
Completed
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000347
Locations
🇺🇸

Friends Research Institute, Los Angeles, California, United States

Early Phase II Trials for Cocaine Medication Development - 1

Phase 2
Completed
Conditions
Cocaine-Related Disorders
Substance-Related Disorders
Interventions
Drug: Placebo
Behavioral: Relapse prevention counseling
First Posted Date
1999-09-21
Last Posted Date
2017-06-26
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
31
Registration Number
NCT00000317
Locations
🇺🇸

NYS Psychiatric Institute, New York, New York, United States

Risperidone Treatment in Dually-Diagnosed Individuals - 2

Phase 2
Completed
Conditions
Cocaine-Related Disorders
First Posted Date
1999-09-21
Last Posted Date
2017-01-12
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Registration Number
NCT00000267
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath